ArticleJournal of controlled release : official journal of the Controlled Release Society2016
Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 69 citations in OpenAlex.
- Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Recent advances in gene delivery for melanocyte-associated disorders.Advanced drug delivery reviews · 2025Review
- Influence of Choline-Based Ionogel on Transdermal Delivery of Vancomycin Hydrochloride.Molecular pharmaceutics · 2025Article
- Design Principles and Applications of Ionic Liquids for Transdermal Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Ionic Liquid-Based Immunization Patch for the Transdermal Delivery of Antigens.Molecules (Basel, Switzerland) · 2024Article
- Effect of Ionic Liquid on Silver-Nanoparticle-ComplexedPharmaceutics · 2023Article
- Improved Topical Drug Delivery: Role of Permeation Enhancers and Advanced Approaches.Pharmaceutics · 2022Review
- Anti-Inflammatory microRNAs for Treating Inflammatory Skin Diseases.Biomolecules · 2022Review
- Novel Pharmaceutical Strategies for Enhancing Skin Penetration of Biomacromolecules.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Structural Dynamics of RNA in the Presence of Choline Amino Acid Based Ionic Liquid: A Spectroscopic and Computational Outlook.ACS central science · 2021Article
- Formulation-based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives.Bioengineering & translational medicine · 2021Review
- Recent Advances in Ionic Liquids in Biomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Ionic liquids: prospects for nucleic acid handling and delivery.Nucleic acids research · 2021Review
- Emerging Nanomedicines for the Treatment of Atopic Dermatitis.AAPS PharmSciTech · 2021Review
- Fractional Laser-Mediated siRNA Delivery for Mitigating Psoriasis-like Lesions via IL-6 Silencing.Molecular therapy. Nucleic acids · 2020Article
- Ionic Liquids as Potential and Synergistic Permeation Enhancers for Transdermal Drug Delivery.Pharmaceutics · 2019Review
- Advances in Biomaterials for Drug Delivery.Advanced materials (Deerfield Beach, Fla.) · 2018Review
- Ionic liquids for addressing unmet needs in healthcare.Bioengineering & translational medicine · 2018Review
- The pH-Triggered Triblock Nanocarrier Enabled Highly Efficient siRNA Delivery for Cancer Therapy.Theranostics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The high prevalence of skin diseases and their visible symptoms result in major physical, emotional, and economic burden for which few solutions exist. To address this unmet medical need, topical delivery of RNAi such as siRNA holds many advantages including direct access to the diseased site, potent knockdown of disease symptoms, and limited off-target effects. Unfortunately, delivering drugs into skin is extremely difficult. To address these concerns, we present RNAi robed with ionic liquid moieties. Specifically, we show that robed-siRNAs can be synthesized by a simple two-step process from bulk materials. Robing affords tuneability of properties necessary for dermal drug delivery including octanol-water partitioning, skin transport, and cell internalization. The efficacy and safety of robed-siRNA for treating skin disease was confirmed by its ability to limit breakdown of elastin, a major cause of premature aging, following UVB exposure to human reconstructed skin tissue. Together, the data strongly support that therapeutic RNAi robed with ionic liquid moieties are a simple, scalable prodrug platform for treating skin disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.